Author/Authors :
Katoh, Shojiro Edogawa Evolutionary Lab of Science, Higashi-Koiwa, Edogawa, Tokyo, Japan , Obayashi, Toshihiko Edogawa Hospital, Higashi-Koiwa, Edogawa, Tokyo, Japan , Ganesh, Jegatheesan Saravana Waikato District Health Board, Hamilton, New Zealand , Iwasaki, Masaru Yamanashi University, Shimokato, Chuo, Yamanashi, Japan , Preethy, Senthilkumar The Fujio-Eiji Academic Terrain (FEAT) - Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, Tamil Nadu, India , Abraham, Samuel JK Yamanashi University, Shimokato, Chuo, Yamanashi, Japan
Abstract :
COronaVIrus Disease 2019 (COVID-19) is an on-going pandemic attributed to a novel virus named SARS-CoV-2.
Comparing the statistics of incidence and death rates between nations reveals that there is discrepancy amongst
countries in these regards, even between countries that share borders. We herein present information from the
literature indicating how cross-protection against COVID-19 conferred by the encephalitis vaccine could be the
reason for lower fatality rate in the countries where immunization against encephalitis is widespread or included
in national programs. This may pave the way for arriving at efficient prevention strategies as well as vaccine
development.
Keywords :
COVID-19 , immunity , heterologous , encephalitis , vaccines , japanese encephalitis vaccines
